
|Articles|December 15, 2005
FDA approves new hyaluronidase formula
Rockville, MD—The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).
Advertisement
Rockville, MD-The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).
The prescription drug was approved as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.
The FDA said it is a proteolytic enzyme and reviewed under a priority review cycle.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5




























